AWM Investment Company Inc. Acquires 128,100 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

AWM Investment Company Inc. boosted its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 22.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 687,831 shares of the company’s stock after buying an additional 128,100 shares during the quarter. AWM Investment Company Inc. owned approximately 2.55% of Alto Neuroscience worth $2,910,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after acquiring an additional 3,139 shares during the last quarter. Deutsche Bank AG lifted its stake in Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in Alto Neuroscience in the fourth quarter valued at approximately $74,000. Jane Street Group LLC boosted its position in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. HC Wainwright began coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They set a “buy” rating and a $10.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Finally, Wedbush reissued a “neutral” rating and set a $4.00 price target on shares of Alto Neuroscience in a research note on Thursday, May 15th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $2.91 on Wednesday. The company has a market capitalization of $78.78 million, a price-to-earnings ratio of -1.24 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $17.55. The stock has a fifty day simple moving average of $2.35 and a 200 day simple moving average of $3.41.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.06. Sell-side analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.